Biosynthetic Cell Membrane Vesicles to Enhance TRAIL-mediated Apoptosis Driven by Photo-triggered Oxidative Stress
Overview
Pharmacology
Affiliations
Due to its tumor-specificity and limited side effects, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has shown great potential in cancer treatments. However, the short half-life of TRAIL protein and the poor death receptor (DR) expression of cancer cells severely compromise the therapeutic outcomes of TRAIL in clinical studies. Herein, a novel ROS-dependent TRAIL-sensitizing nanoplatform, CPT MV, with a Ce6-PLGA core and a TRAIL-modified cell membrane shell was explored to improve the circulation stability of TRAIL and to amplify TRAIL-induced apoptosis. CPT MV could produce ROS in the targeted cells upon laser irradiation to improve death receptor (DR)-5 expression and trigger Cyt c release from mitochondria. When engaged with TRAIL, the up-regulated DR5 could recruit more Fas-associated death domain (FADD) to transport the extrinsic apoptotic signal to the initiator caspase (caspase 8) and then the executioner caspase (caspase 3), while leaked Cyt c could trigger the intrinsic apoptotic pathway to further strengthen TRAIL-induced apoptosis. Therefore, the designed CPT MV could enhance TRAIL-mediated apoptosis driven by photo-triggered oxidative stress, which provides a very promising approach to clinically overcome tumor resistance to TRAIL therapy.
Turn TRAIL Into Better Anticancer Therapeutic Through TRAIL Fusion Proteins.
Wang Y, Qian X, Wang Y, Yu C, Feng L, Zheng X Cancer Med. 2024; 14(1):e70517.
PMID: 39740038 PMC: 11683677. DOI: 10.1002/cam4.70517.
Cai X, Li Y, Zheng J, Liu L, Jiao Z, Lin J Front Oncol. 2024; 13:1291559.
PMID: 38370348 PMC: 10869451. DOI: 10.3389/fonc.2023.1291559.
Yagolovich A, Gasparian M, Dolgikh D Pharmaceutics. 2023; 15(2).
PMID: 36839837 PMC: 9961178. DOI: 10.3390/pharmaceutics15020515.